ResMed
$221.15Change from previous close: +0.02%Absolute change: +$0.05
Valuation
Data as of October 2, 2026
Valuation multiples
- Market cap
- $31.9B
- Enterprise value
- $31.26B
- P/E (trailing 12 months)
- 21.2
- Forward P/E
- 16.7
- PEG
- 1.28
- Price/book
- 4.84
- Price/sales
- 5.64
- EV/EBITDA
- 14.9
- EV/revenue
- 5.53
Profitability and growth
- Gross margin
- 61.6%
- Operating margin
- 30.9%
- Net margin
- 26.9%
- ROE
- 24.3%
- ROA
- 14.0%
- Revenue growth (year over year)
- 8.6%
- Earnings growth (year over year)
- 2.4%
Financial health
- Total cash
- $1.47B
- Total debt
- $825.92M
- Debt/equity
- 0.13
- Current ratio
- 3.10
- Quick ratio
- 1.83
Dividends
- Annual dividend per share
- $2.64
- Dividend yield
- 1.2%
- Payout ratio
- 23.0%
- Ex-dividend date
- August 20, 2026
Analysts and estimates
- Average price target
- $250.22
- Median price target
- $235.00
- High price target
- $320.00
- Low price target
- $175.00
- Analysts with a price target
- 17
- Consensus
- Buy
- Forward EPS
- $13.23
- EPS estimate, current year
- $12.09
Shares and trading
- Beta
- 0.77
- Average volume
- 1.41M
- Shares outstanding
- 144.25M
- Float
- 143.36M
- Institutional ownership
- 71.2%
- Insider ownership
- 0.5%
- Short interest (% of float)
- 11.4%
- Short ratio (days)
- 10.6